“We look forward to discussions with regulatory authorities with the goal of bringing this new treatment option to patients as soon as possible.” “We are highly encouraged by these positive results with adjuvant Kadcyla treatment in people with HER2-positive early breast cancer who have residual disease after neoadjuvant therapy,” said Sandra Horning, MD, chief medical officer and head of Global Product Development, Genentech. Full data will be presented at the 2018 San Antonio Breast Cancer Symposium and will be submitted to the FDA and European Medicines Agency, Genentech (Roche), the developer of the antibody-drug conjugate, stated in a news release. Moreover, no new safety signals with T-DM1 were reported and the safety profile was consistent with prior studies of the agent.
#T dm1 adjuvant update
UPDATE : T-DM1 Likely New Adjuvant Standard in High-Risk HER2+ Breast Cancer Ado-trastuzumab emtansine (T-DM1 Kadcyla) was found to significantly reduce the risk of invasive disease recurrence or death compared with trastuzumab (Herceptin) as an adjuvant treatment in patients with HER2-positive early breast cancer who have residual disease following neoadjuvant therapy, according to topline findings of the phase III KATHERINE study.
0 kommentar(er)
